CAMBRIDGE, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Idera Pharmaceuticals,
Inc. (Amex: IDP) announced today that Timothy Sullivan, Ph.D., Vice President
of Development Programs, is scheduled to present an overview of the Company,
its product pipeline, and its technology to investors at the Rodman & Renshaw
Techvest 7th Annual Healthcare Conference, taking place at The New York Palace
Hotel in New York City. The presentation is scheduled for Monday, November 7,
2005 at 1:00 p.m. ET in the Kennedy I room.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. is a biotechnology company focused on the
discovery, development, and commercialization of targeted immune therapies
based on modulation of Toll-like Receptors (TLRs). Idera has identified novel
chemical entities that modulate immune responses through interactions with
TLR9. The Company continues to identify new drug candidates specific to
various diseases, including cancer, infectious diseases and asthma/allergies,
based on the differentiated biological activities of its proprietary
compounds. The Company's website is located at http://www.iderapharma.com.
Idera Pharmaceuticals (Amex: IDP) is based in Cambridge, Massachusetts.
Idera's lead candidate is IMO-2055, a TLR9 agonist currently in Phase 2
clinical testing for cancer. Idera is also collaborating with Novartis for
the discovery, development, and commercialization of IMO drug candidates
targeting asthma and allergies.
Forward-Looking Statements
This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For
this purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. Without
limiting the foregoing, the words "believes," "anticipates," "plans,"
"expects," "estimates," "intends," "should," "could," "will," "may," and
similar expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's actual
results to differ materially from those indicated by such forward-looking
statements, including whether products based on Idera's technology will
advance through the clinical trial process on a timely basis or at all and
receive approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if such products receive
approval, they will be successfully distributed and marketed; whether Idera's
cash resources will be sufficient to fund product development and clinical
trials; and such other important factors as are set forth under the caption
"Risk Factors" in Idera's Quarterly Report on Form 10-Q filed on August 9,
2005, which important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements.
Contacts:
Idera Pharmaceuticals, Inc. MacDougall Biomedical Communications
617-679-5500 x5517 508-647-0209 x12
Robert G. Andersen Douglas MacDougall
E-mail: randersen@iderapharma.com E-mail: doug@macbiocom.com
SOURCE Idera Pharmaceuticals, Inc.
 back to top
Related links:
http://www.iderapharma.com
CONTACT:
Robert G. Andersen of Idera Pharmaceuticals,
Inc., +1-617-679- 5500 ext. 5517, randersen@iderapharma.com; or
Douglas MacDougall of MacDougall Biomedical Communications,
+1-508-647-0209 ext. 12, doug@macbiocom.com
|
